BDX Stock Forecast & Price Target

Becton Dickinson's financial performance showcases a consistent upward trajectory, with the Medical Surgical Solutions (MMS) segment reporting sales of $888 million in FQ3'25, representing a year-over-year increase of 5.3%, driven by strong demand in Infusion Systems and Dispensing Solutions. Additionally, the company's broader MedTech business has experienced annual growth exceeding 6% since the launch of BD 2025, accompanied by improving margins, indicating a robust operational efficiency. Furthermore, the MDS segment achieved FY24 sales of $4.43 billion, showing a year-over-year increase of 3.2% (ex-fx), highlighting the solid fundamentals underlying Becton Dickinson's positive growth outlook in the medical sector.

Becton Dickinson's reaffirmation of its organic revenue growth outlook at 3.0-3.5% y/y, down from a prior forecast of 4.0-4.5%, indicates weakening growth expectations and raises concerns about the company's ability to meet previous performance levels. In its recent financial quarter, the company reported $1.25 billion in sales, reflecting a 1.1% decline year-over-year, predominantly driven by low-single-digit declines in critical segments such as Biosciences and Diagnostic Solutions. Additionally, challenges such as volume-based procurement headwinds in China and reduced demand in the Biosciences sector, exacerbated by government cuts to research grants, further contribute to a negative outlook on the company's financial health.